The unselected PROPEL trial showed a broad population benefit, but regulators ultimately restricted its PARP+ARPI approval to BRCA-mutated patients. This aligns with the MAGNITUDE trial, which used prospective selection and halted its non-biomarker arm for futility, validating the necessity of pre-planned genomic stratification.

The SERENA-6 trial showed improved survival by switching therapy upon ctDNA detection of ESR1 mutations. However, it required screening over 3,300 patients to randomize just 315, highlighting the immense scale, cost, and patient drop-off of applying this serial monitoring strategy in standard clinical practice.

ESR1 mutations are rarely found in primary tumors but develop in metastatic settings under pressure from aromatase inhibitors, conferring resistance. This evolution necessitates serial, plasma-based genotyping upon each disease progression to identify these actionable mutations as they emerge.

The SERINA-6 trial suggests a paradigm shift: proactively switching from an AI to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical or radiographic progression—significantly improves progression-free survival and patient quality of life.

SERENNA-six pioneers a strategy where treatment is switched upon detecting an ESR1 resistance mutation in ctDNA, *before* the patient shows clinical signs of progression. This proactive, biomarker-driven approach represents a paradigm shift from reactive treatment of progressing disease.

Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.

The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.

The SERENA-6 trial tested a hypothesis rooted in evolutionary biology: intervening when a resistance mutation (ESR1) first appears in ctDNA, while the clone is small and less diverse, rather than waiting for clinical progression. This proactive approach aims to control resistance before it becomes dominant and harder to treat.

The trial showed a profound 100% median reduction in ESR1 mutation frequency in the camisestrant arm versus a 66% increase in the control arm. This provides a powerful pharmacodynamic signal that the drug is potently inhibiting its intended target—the mutated estrogen receptor—and offers a clear molecular rationale for its clinical efficacy.